Trial investigators are actively seeking people with amyotrophic lateral sclerosis (ALS) to participate in a phase 2 clinical trial that will evaluate the effects of a five-drug treatment regimen used to suppress immune system activity.
The U.S. Department of Veterans Affairs (VA) is seeking veterans who have amyotrophic lateral sclerosis (ALS) and who live in the United States to enroll in its VA Biorepository Brain Bank (VABBB), a human tissue bank that collects, processes and stores tissue samples for use in future research studies.
A failure to repair damaged DNA appears to play an important role in amyotrophic lateral sclerosis (ALS), an MDA-supported team of researchers reports.
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:
This roundup of recent MDA-supported amyotrophic lateral sclerosis (ALS) research news and reviews includes:
The U.S. Food and Drug Administration (FDA) has given the go-ahead to the nonprofit biotech ALS Therapy Development Institute (ALS TDI) to conduct a clinical trial of TDI132 — also known as fingolimod, or the brand name Gilenya— in people withALS (amyotrophic lateral sclerosis).
Muscular Dystrophy Association — USA
National Office222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606(800) 572-1717
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2015, Muscular Dystrophy Association Inc. All rights reserved.